On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

A source of the parasites has not yet been found. The Food and Drug Administration first reported the outbreak on Aug. 7 and the patient count has steadily… A Codex committee has made progress ...

The target of the strike in Lebanon was the group’s leader, Hassan Nasrallah, according to Israeli and American officials. The attack came shortly after the Israeli prime minister gave a defiant ...

Israel will continue to discuss ceasefire proposals for Lebanon in the days ahead, Prime Minister Benjamin Netanyahu said on Friday, as Washington warned that further escalation would only make it ...